Short Interest in Onconetix, Inc. (NASDAQ:ONCO) Declines By 99.2%

Onconetix, Inc. (NASDAQ:ONCO) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 5,900 shares, a drop of 99.2% from the August 31st total of 695,100 shares. Currently, 0.9% of the shares of the company are short sold. Based on an average daily volume of 245,300 shares, the short-interest ratio is currently 0.0 days.

Onconetix Price Performance

Shares of NASDAQ ONCO opened at $3.36 on Friday. The company has a current ratio of 0.10, a quick ratio of 0.09 and a debt-to-equity ratio of 0.08. Onconetix has a 12 month low of $2.82 and a 12 month high of $23.05. The stock has a 50 day moving average of $0.28 and a 200-day moving average of $0.20.

Onconetix (NASDAQ:ONCO) last released its quarterly earnings data on Thursday, August 29th. The company reported ($0.23) EPS for the quarter. The business had revenue of $0.71 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Onconetix, Inc. (NASDAQ:ONCO) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned 1.37% of Onconetix as of its most recent SEC filing. 23.89% of the stock is owned by institutional investors.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.